Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PerkinElmer (NY: PKI )

138.56 +3.60 (+2.67%)
Official Closing Price Updated: 7:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 504,179
Open 134.54
Bid (Size) 136.88 (1)
Ask (Size) 140.15 (1)
Prev. Close 134.96
Today's Range 133.02 - 139.15
52wk Range 113.46 - 190.56
Shares Outstanding 112,114,149
Dividend Yield 0.20%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
PerkinElmer Board Declares Quarterly Dividend
From PerkinElmer, Inc.
Via Business Wire
The Latest Analyst Ratings for PerkinElmer
 
Via Benzinga

Performance

YTD
-1.83%
-1.83%
1 Month
-3.00%
-3.00%
3 Month
+3.73%
+3.73%
6 Month
-13.87%
-13.87%
1 Year
-18.22%
-18.22%

More News

Read More
PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter Outlook
From PerkinElmer Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Via Benzinga
5 Analysts Have This to Say About PerkinElmer
Via Benzinga
PerkinElmer to Present at J.P. Morgan Healthcare Conference
From PerkinElmer Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
PerkinElmer Clocks Lower Quarterly Earnings, But Beat Expectations
Via Benzinga
Analyst Ratings for PerkinElmer
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday
Via Benzinga
8 Of The Top Canadian Value Stocks To Buy In December 2022
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022
Via Benzinga
PerkinElmer Helps Accelerate Gene Therapy Research with Industry-First Ready-to-Use Viral Vector Assays
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns
From PerkinElmer Inc.
Via Business Wire
PerkinElmer to Present at 2022 Stifel Healthcare Conference
From PerkinElmer Inc.
Via Business Wire
PerkinElmer Announces Financial Results for the Third Quarter of 2022
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Bolsters Sustainability Commitments and Builds Off Recent Progress in New ESG Report
From PerkinElmer Inc.
Via Business Wire
PerkinElmer Board Declares Quarterly Dividend
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Sweetens Its Outlook And Shares Surge, But There's Still One Hitch
Via Investor's Business Daily
PerkinElmer to Hold Earnings Call on Tuesday, November 8, 2022; Updates Third Quarter Outlook
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Donation Helps Significantly Expand Capacity for Sickle Cell Disease Screening in Ghana
From PerkinElmer Inc.
Via Business Wire
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Via Benzinga
PerkinElmer Unveils Industry-first Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing
From PerkinElmer, Inc.
Via Business Wire
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.